Tag:adderall
Adderall Shortages: Regulatory Compliance and Enforcement Risks in the Big-Pharma Ecosystem
Since October 2022, the United States has been grappling with an ongoing shortage of Adderall, a cornerstone prescription stimulant for millions of Americans. What began as intermittent shortages due to manufacturing disruptions has evolved into a prolonged supply constraint affecting patients, providers, and regulators. Behind this shortage lies a complex overlap of regulatory frameworks, legal reporting obligations, and compliance risks that are present across the pharmaceutical industry. Thus, the Adderall shortage is not simply a manufacturing hiccup. It is a case study in how overlapping regulatory regimes can collectively constrain supply in ways that neither regulators nor companies can easily fix in real time. Thus, ensuring sustainable access to ADHD medications and promoting proper use will require clearer authority, better data integration, and shared accountability across drug regulators and the Big-Pharma industry. Without these reforms, shortages will remain a recurring crisis to manage, rather than a systemic problem to prevent.
DEA Attempts to Regulate Telehealth Prescription of ADHD Medication
The U.S. Food and Drug Administration (FDA) and the U.S. Drug Enforcement Administration (DEA) have guarded controlled substances zealously since the inception of the Controlled Substances Act (CSA), passed in the 1970s. However, the coronavirus (COVID-19) pandemic challenged nearly all of society’s conventional protocols, and the federal government responded to concerns that patients wouldn’t receive care by loosening its regulations for healthcare services. In 2020, the DEA permitted health providers to prescribe schedule II-controlled substances to patients via telehealth appointments instead of in-person visits. Now, two years later, the FDA has confirmed an Adderall shortage, which is a schedule II controlled substance that is in high demand and used to treat attention-deficit/hyperactivity disorder (ADHD). The Justice Department’s DEA division has initiated probes against various online mental health companies and worries that the drug is overprescribed and abused by young adults.